Back to top
more

AVEO Pharmaceuticals, Inc. (AVEO)

(Delayed Data from NSDQ)

$0.94 USD

0.94
1,186,754

+0.04 (4.01%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.91 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

New Strong Sell Stocks for July 1st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

FDA Okays AVEO's NDA Filing for Treating Renal Cell Carcinoma

AVEO's new drug application submission for tivozanib as a treatment of relapsed or refractory renal cell carcinoma gets acceptance from the FDA. A decision is expected on Mar 31, 2021.

Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

Why Is AVEO (AVEO) Up 24.8% Since Last Earnings Report?

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why You Shouldn't Bet Against AVEO Pharmaceuticals (AVEO) Stock

AVEO Pharmaceuticals (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Lags Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of -4.00% and -65.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

AVEO (AVEO) Up 39.9% Since Last Earnings Report: Can It Continue?

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic

AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.

AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat & Sales Miss

Even though AVEO Pharmaceuticals (AVEO) reports narrower-than-estimated loss in the fourth quarter, its revenues miss the mark.

AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Lags Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 51.72% and -63.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CannTrust (CTST) to Report Q4 Earnings: What's in Store?

During CannTrust's (CTST) fourth-quarter earnings call, investor focus will be on the updates pertaining to the company's default status reports and completion of its remediation activities.

What's in Store for Axsome (AXSM) This Earnings Season?

On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

What Lies Ahead for Cassava Sciences (SAVA) in Q4 Earnings?

During the Q4 investors' call, Cassava Sciences (SAVA) is likely to provide an update on its lead candidate PT-125, which is being developed for the treatment of Alzheimer's disease.

Onconova (ONTX) to Report Q4 Earnings: What's in Store?

Onconova (ONTX) will focus on the updates on lead candidate, Rigosertib, when it reports fourth-quarter 2019 results.

Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?

During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.

What Makes AVEO (AVEO) a New Buy Stock

AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study

AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.

Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

Why Is AVEO (AVEO) Down 0.1% Since Last Earnings Report?

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal

Sarepta (SRPT) expands its footing in the gene therapy field and signs a deal with StrideBio to develop up to eight new treatments.

AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark

AVEO Pharmaceuticals (AVEO) rides high on both earnings and revenue beat in the third quarter. Shares rise.

Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis

Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.

Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus

Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.

Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales

Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.